Vanda Pharmaceuticals (VNDA) Stock Analysis & Winston Score

Vanda Pharmaceuticals is a small drug company that makes medicines for rare and hard-to-treat conditions. Its main products are Hetlioz, used to treat a sleep disorder called Non-24-Hour Sleep-Wake Disorder (common in blind people), and Fanapt, an antipsychotic medication for schizophrenia. The company sells these drugs primarily in the United States through prescriptions written by doctors. Vanda makes money by selling its approved drugs directly to pharmacies and specialty distributors. Its very high gross margin reflects the typical economics of branded pharmaceuticals, but the deeply negative operating margin shows the company is spending heavily — likely on research and legal battles to protect its drug patents. Vanda operates mainly in the U.S. and is quite small, with a market cap around $300 million. The biggest risk the company faces is patent expiration and generic competition, which could sharply cut revenue from its existing products if pipeline drugs do not reach the market in time.